Theriva Biologics (NYSE American: TOVX), is a diversified clinical-stage company developing therapeutics designed to treat diseases in areas of high unmet need. The Company advanced into oncology through the acquisition of VCN Biosciences, S.L. (VCN), who have developed a new oncolytic adenovirus platform designed for intravenous (IV), intravitreal and antitumoral delivery to trigger tumor cell death, improve access of co-administered cancer therapies to the tumor, and promote a robust and sustained anti-tumor response by the patient’s immune system. The Company’s lead candidates are: (1) VCN-01, an oncolytic adenovirus designed to replicate selectively and aggressively within tumor cells, and to degrade the tumor stroma barrier that serves as a significant physical and immunosuppressive barrier to cancer treatment; (2) SYN-004 (ribaxamase) which is designed to degrade certain commonly used IV beta-lactam antibiotics within the gastrointestinal (GI) tract to prevent (a) microbiome damage, (b) Clostridioides difficile infection (CDI), (c) overgrowth of pathogenic organisms, (d) the emergence of antimicrobial resistance (AMR), and (e) acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant (HCT) recipients, and (3) SYN-020, a recombinant oral formulation of the enzyme intestinal alkaline phosphatase (IAP) produced under cGMP conditions and intended to treat both local GI and systemic diseases.
Company Details
- Employees
- 22
- Address
- 9605 Medical Center Drive,
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- syntheticbiologics.com
- Keywords
- Microbiome, Prevention of C. dificile Infection, Irritable Bowel Syndrome with Constipation (IBS-C), Clinical Development, Drug discovery, Preservation of natural gut microbiome, oncology, oncolytic virus, cancer.
- HQ
- Rockville, Maryland
Theriva Biologics, Inc. Questions
Theriva Biologics, Inc.'s website is syntheticbiologics.com
Theriva Biologics, Inc.'s LinkedIn profile is https://www.linkedin.com/company/theriva-biologics
Theriva Biologics, Inc. has
22 employees.
View email and phone details for 22
employees at Theriva Biologics, Inc..
Theriva Biologics, Inc.'s industry is
Biotechnology Research
Theriva Biologics, Inc.'s top competitors are
Fuse Vectors,
Atlyphe Ag,
Gene Vector,
Ikarovec,
Phoenestra Gmbh,
Liberabio,
Rise Therapeutics,
Theriva Biologics (Formerly Vcn Biosciences),
Glyprovac,
Serendip Innovations.
Theriva Biologics, Inc.'s categories are Biotechnology Research
